Holen Sie sich die Stockscreener-App
181.82
0.51%
1.07
Handel nachbörslich:
182.00
0.18
+0.10%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$180.75
Offen:
$181.86
24-Stunden-Volumen:
754.03K
Relative Volume:
0.42
Marktkapitalisierung:
$26.67B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
17.39
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
-0.15%
1M Leistung:
+21.66%
6M Leistung:
+37.77%
1J Leistung:
+12.89%
1-Tages-Spanne:
$179.27
$182.69
1-Wochen-Bereich:
$174.53
$182.94
52-Wochen-Spanne:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
181.82 | 26.52B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,013.85 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.69 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.45 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option - MarketScreener
Biosimilars and Biologics Market is expected to reach US$ - openPR.com
Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors? - simplywall.st
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment - GuruFocus
Eisai and Biogen Present Long-Term LEQEMBI Data Indicating Potential Delay in Alzheimer's Disease Progression by Up to 8.3 Years - Quiver Quantitative
Biogen’s strategic turn to New Ventures - biocentury.com
BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs - TradingView
Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference - MarketScreener
Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Tr - GuruFocus
Lecanemab shows effect on Alzheimer’s biomarkers in new study By Investing.com - Investing.com India
Biogen (BIIB): Assessing Valuation After Recent Share Price Gains - Yahoo Finance
Lecanemab shows effect on Alzheimer’s biomarkers in new study - Investing.com
Eisai and Biogen Present New Findings on Lecanemab's Effects on Alzheimer’s Disease at CTAD Conference - Quiver Quantitative
Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 - MarketScreener
I Remember Aduhelm. The Return of Roche in Alzheimer’s Is a Turning Point - BioSpace
Does Biogen’s Valuation Stack Up After Recent Alzheimer’s Regulatory Updates? - simplywall.st
Multiple Sclerosis Therapeutics Market Growth Accelerates - openPR.com
What insider trading reveals about Biogen Inc. stockTrade Signal Summary & Long-Term Safe Investment Plans - Newser
Will Biogen Inc. stock deliver shareholder valueJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
Transforming Growth Factor Beta Pipeline Drugs Insights Report - openPR.com
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Me - PharmiWeb.com
Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Biogen
A Look at Biogen's Valuation as It Expands Immunology Pipeline With Dayra Therapeutics Collaboration - simplywall.st
BIIBBiogen Inc Stock Price and Quote - Finviz
Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week - Proactive Investors
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Benzinga
Biogen shares could climb on Leqembi uptake – Jefferies - Proactive financial news
Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection - MarketScreener
Jefferies Adjusts Price Target on Biogen to $210 From $190, Maintains Buy Rating - MarketScreener
Eisai and Biogen Submit New Drug Application for Subcutaneous LEQEMBI® to Japan's PMDA - Quiver Quantitative
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - Biogen
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan - GlobeNewswire Inc.
Will Biogen Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly High Return Opportunities - moha.gov.vn
How Recent Developments Are Rewriting the Story for Biogen - Yahoo Finance
Total debt per share of Biogen Inc. – DUS:IDP - TradingView
Health Plans Defend Renewed Biogen MS Drug Scheme Suit - Law360
Biogen's $50 Million Immunology Power Move: Are Oral Peptides The Future? - Smartkarma
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc. - Wilson Sonsini
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - ACN Newswire
Avoiding Lag: Real-Time Signals in (BIIB) Movement - news.stocktradersdaily.com
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical DeclineJohnson & Johnson (NYSE:JNJ) - Benzinga
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline - Finviz
Biogen (BIIB) Advances Alzheimer's Treatment with FDA Submission - GuruFocus
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Biogen
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - PR Newswire
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership - MarketScreener
Why Biogen (BIIB) Is Up 7.4% After Announcing Dayra Immunology Collaboration and Pipeline Expansion - simplywall.st
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report - biocentury.com
Biogen Joins The Macrocycle Melee With Dayra Tie-Up - Citeline News & Insights
Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares. - Barron's
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grogan Jane | Head of Research |
Oct 31 '25 |
Option Exercise |
0.00 |
695 |
0 |
2,128 |
| Godbout Sean | Chief Accounting Officer |
Oct 02 '25 |
Option Exercise |
0.00 |
26 |
0 |
503 |
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
1.52%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):